RPS19

Small ribosomal subunit protein eS19 · P39019 · RPS19 on Sugi Atlas →

3,676 patent compounds predicted against RPS19, 1,926 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5500526	0.41	4/20
SCHEMBL5500532	0.41	4/20
SCHEMBL5503310	0.41	4/20
SCHEMBL11844361	0.35	4/20
SCHEMBL2000440	0.39	3/20
SCHEMBL8219903	0.36	3/20
SCHEMBL11627320	0.34	3/20
SCHEMBL10271044	0.55	2/20
SCHEMBL6394396	0.47	2/20
N-Methylpiperidine (SCHEMBL11205373)	0.42	2/20
Bicarbonate (SCHEMBL9058396)	0.42	2/20
SCHEMBL4960293	0.41	2/20
SCHEMBL4961968	0.40	2/20
SCHEMBL6686992	0.40	2/20
SCHEMBL9429122	0.38	2/20
Chloramphenicol (SCHEMBL10796001)	1.00	1/20
Geneticin (SCHEMBL15596)	0.93	1/20
Geneticin (SCHEMBL5006573)	0.93	1/20
Geneticin (SCHEMBL9920496)	0.93	1/20
Chloramphenicol (SCHEMBL16111)	0.90	1/20

Clinical trials — most relevant to RPS19 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan Anemia	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer	PHASE1/PHASE2	COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	PHASE2	COMPLETED
Prospective Phase II Randomized Trial of Postoperative Adjuvant Chemotherapy in Patients With High Risk Colon Cancer	PHASE2	UNKNOWN
Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia	PHASE1	RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	PHASE1	WITHDRAWN
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment	PHASE1	COMPLETED
Safety and Tolerance of RAG-17 in Amyotrophic Lateral Sclerosis Patients With SOD1 Gene Mutation	EARLY_PHASE1	COMPLETED
Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)	nan	RECRUITING
Testing of Micellar Casein, Blended Micellar Casein and Native Whey	nan	COMPLETED
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma	nan	COMPLETED
RibOSE - Glucose and Resistance Exercise Training	nan	COMPLETED
Genomic of CONgenital Sideroblastic Anemias	nan	RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer	nan	UNKNOWN
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases	nan	UNKNOWN
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care	nan	COMPLETED
Choroid Plexus Dysfunction in Neurological Diseases	nan	RECRUITING
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
Intrauterine Environment in Polycystic Ovary Syndrome (PCOS) Probands	nan	COMPLETED
Trichomonas Vaginalis Genotyping in Upper Egypt	nan	UNKNOWN
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
Role of RPL8 Protein Alterations in High-grade Serous Ovarian Carcinoma	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a RPS19 binder may also engage these)

Protein	Name	Similarity
Q5R8M9	—	1.000	Q5R8M9 →
Q32PD5	—	1.000	Q32PD5 →
P17074	—	1.000	P17074 →
Q9CZX8	—	1.000	Q9CZX8 →
P61155	—	1.000	P61155 →
G1TN62	—	1.000	G1TN62 →
Q9DFR5	—	1.000	Q9DFR5 →
Q8T5Z4	—	1.000	Q8T5Z4 →
Q9FNP8	—	0.999	Q9FNP8 →
Q90YQ4	—	0.999	Q90YQ4 →
Q29308	—	0.998	Q29308 →
P24494	—	0.997	P24494 →
P58234	—	0.997	P58234 →
O28210	—	0.997	O28210 →
P27073	—	0.997	P27073 →
Q9LF30	—	0.996	Q9LF30 →
Q9Y0H3	—	0.996	Q9Y0H3 →
P40978	—	0.996	P40978 →
P79016	—	0.995	P79016 →
O18650	—	0.995	O18650 →
Q54X51	—	0.995	Q54X51 →
Q9YD22	—	0.994	Q9YD22 →
P07281	—	0.994	P07281 →
P07280	—	0.993	P07280 →
Q9SGA6	—	0.993	Q9SGA6 →
A0A1D8PK61	—	0.993	A0A1D8PK61 →
Q8ITC3	—	0.992	Q8ITC3 →
P39018	—	0.992	P39018 →
P39698	—	0.990	P39698 →
Q7KS38	—	0.989	Q7KS38 →